ClinicalTrials.gg
TerminatedNCT03123588Updated Nov 19, 2021Results posted

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

A Phase 2 interventional study of Ruxolitinib and Anagrelide in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Terminated at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Primary conditionThrombocythemia, EssentialRegistry: Myeloproliferative DisordersReclassifiedWhy we changed it
Registry
Myeloproliferative Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Thrombocythemia, Essential
Why
  1. The study's title name Thrombocythemia, Essential, a narrower term within Myeloproliferative Disorders.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.

Enrollment
103rd of 120
12 · median 45
Started
2017
the only one that year
Phase 2
49 of 149
6 open now
Registered
115th of 149
by date
Lead sponsor
7 of 149
Incyte Corporation

Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is the only one that started in 2017, is one of 49 in phase 2, and was the 115th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Thrombocythemia, Essential with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

03

Conditions studied

  • MPN (Myeloproliferative Neoplasms)

Browse trials for

Keywords

  • Essential thrombocythemia
  • hydroxyurea-resistant
  • hydroxyurea-intolerant
  • ruxolitinib
  • anagrelide
04

In context

Thrombocythemia, Essential Reclassified

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

This study's enrollment of 12 is below the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.

Browse Thrombocythemia, Essential studies →

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Compared within Thrombocythemia, Essential, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myeloproliferative Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.
  • Resistant to or intolerant of hydroxyurea, that is, fulfilling at least 1 of the following criteria:

    • count > 600 × 10\^9/L after 3 months of at least 2 g/day of hydroxyurea (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is \< 2 g/day.
    • Platelet count > 400 × 10\^9/L and WBC count \< 2.5 × 10\^9/L or \< 10 g/dL at any dose of hydroxyurea.
    • Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of hydroxyurea.
    • Hydroxyurea-related fever.
  • Platelet count ≥ 650 × 10\^9/L at screening.
  • WBC ≥ 11.0 × 10\^9/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Subjects previously treated with anagrelide or Hydroxyurea (HU).

    1. Prior anagrelide use is allowed provided the reason for discontinuation is not AE-related and anagrelide is stopped at least 28 days before the start of study medications (ie, Day 1).
    2. Treatment with HU can be stopped at any time once one of the inclusion criteria for HU refractoriness or resistance have been met, and up to the day before the first dose of study treatment (ie, Day 1).
  • Inadequate liver function at screening and Day 1 (before drug administration) as demonstrated by:

    • Total > 1.5 × (ULN)
    • or alanine aminotransferase > 1.5 × ULN
    • Hepatocellular disease (eg, cirrhosis)
  • Inadequate renal function at screening as demonstrated by \< 40 mL/min calculated by Cockcroft-Gault equation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group A : Ruxolitinib and anagrelide placebo

    Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.

    Drug: Ruxolitinib · Drug: Placebo

  • Active comparator
    Group B : Anagrelide and Ruxolitinib PLacebo

    Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.

    Drug: Anagrelide · Drug: Placebo

Interventions

  • Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.

    Also known as: Jakafi, INCB018424

  • Anagrelide administered orally at a starting dose of 1 mg BID.

  • DrugPlacebo

    Anagrelide-placebo administered orally BID

  • DrugPlacebo

    Ruxolitinib-placebo administered orally BID.

07

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control

    Defined as proportion of subjects who achieve a simultaneous reduction of platelet counts to \< 600 × 10\^9/L with a reduction of WBC counts to \< 10 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

    Time frame: 52 weeks

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: Baseline through the end of randomized period -up to 14 months per participant

  2. Proportion of Subjects Who Achieve Complete Remission or Partial Remission

    Defined as proportion of subjects who achieve CR or PR at Week 32 based on European LeukemiaNet (ELN) 2013 response criteria. Per ELN criteria: Complete Remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease and bone marrow histological remission including disappearance of megakaryocyte hyperplasia and absence of reticulin fibrosis \>Grade 1. Partial remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease, persistance of megakaryocyte hyperplasia. No response: any response that does not satisfy partial remission. Progressive Disease: transformation in PET-MF, MDS or acute leukemia.

    Time frame: 32 weeks

  3. Time to Treatment Discontinuation

    Defined as the time when treatment is discontinued

    Time frame: 98 weeks

  4. Duration of Response

    Defined as measurement of response from the onset of response to the loss of response for responders.

    Time frame: 142 weeks

  5. Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L

    Defined as Proportion of subjects who achieve reduction of platelet counts to \< 600 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

    Time frame: Between 32 and 52 weeks

  6. Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L

    Defined as Proportion of subjects who achieve a reduction of WBC counts to \< 10 × 109/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

    Time frame: 52 weeks

08

Results

Posted Nov 19, 2021

Participant flow

Approximately 120 participants were planned for enrollment and 12 participants were enrolled (6 in the ruxolitinib group and 6 in the anagrelide group). The first participant was dosed on 14 Nov 2017 and Last participant completed study on 03 Aug 2020

Participant flow — Overall Study
MilestoneGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
Started66
Completed00
Not completed66
Withdrew: Study terminated by sponsor25
Withdrew: Withdrawal by subject10
Withdrew: Adverse event10
Withdrew: Physician decision21

Outcome measures

PrimaryProportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control

Defined as proportion of subjects who achieve a simultaneous reduction of platelet counts to \< 600 × 10\^9/L with a reduction of WBC counts to \< 10 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

Time frame:
52 weeks
Reported as:
Number · proportion of participants
Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control
proportion of participantsGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PLacebo
Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control00.17
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

Time frame:
Baseline through the end of randomized period -up to 14 months per participant
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PLacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)54
SecondaryProportion of Subjects Who Achieve Complete Remission or Partial Remission

Defined as proportion of subjects who achieve CR or PR at Week 32 based on European LeukemiaNet (ELN) 2013 response criteria. Per ELN criteria: Complete Remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease and bone marrow histological remission including disappearance of megakaryocyte hyperplasia and absence of reticulin fibrosis \>Grade 1. Partial remission: durable resolution of disease related signs and symptoms, durable blood count normalization, absence of hemorrhagic or thrombotic events, absence of signs of progressive disease, persistance of megakaryocyte hyperplasia. No response: any response that does not satisfy partial remission. Progressive Disease: transformation in PET-MF, MDS or acute leukemia.

Time frame:
32 weeks
Reported as:
Number · proportion of participants
Proportion of Subjects Who Achieve Complete Remission or Partial Remission
proportion of participantsGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
Proportion of Subjects Who Achieve Complete Remission or Partial Remission00.17
SecondaryTime to Treatment Discontinuation

Defined as the time when treatment is discontinued

Time frame:
98 weeks
Reported as:
Mean · Days
Time to Treatment Discontinuation
DaysGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
Time to Treatment Discontinuation261.2 ± 238.85437.2 ± 183.99
SecondaryDuration of Response

Defined as measurement of response from the onset of response to the loss of response for responders.

Time frame:
142 weeks
Reported as:
Number · Days
Duration of Response
DaysGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PLacebo
Duration of Response—442
SecondaryProportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L

Defined as Proportion of subjects who achieve reduction of platelet counts to \< 600 × 10\^9/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

Time frame:
Between 32 and 52 weeks
Reported as:
Number · Proportion of participants
Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L
Proportion of participantsGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L00.50
SecondaryProportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L

Defined as Proportion of subjects who achieve a reduction of WBC counts to \< 10 × 109/L for at least 80% of biweekly measurements for a consecutive 12-week period between Weeks 32 and 52.

Time frame:
52 weeks
Reported as:
Number · Proportion of participants
Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L
Proportion of participantsGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PLacebo
Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L00.33

Adverse events

Collected over Baseline through the end of randomized period -up to 14 months per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A : Ruxolitinib and Anagrelide Placebo0/5 (0%)0/5 (0%)5/5 (100%)
Group B : Anagrelide and Ruxolitinib Placebo0/6 (0%)1/6 (16.7%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/51/6
Most frequent other events
Showing 10 of 46
Most frequent other events
EventGroup A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib Placebo
FatigueGeneral disorders3/50/6
AnaemiaBlood and lymphatic system disorders2/50/6
DiarrhoeaGastrointestinal disorders0/52/6
NauseaGastrointestinal disorders1/52/6
Oedema peripheralGeneral disorders0/52/6
PruritusSkin and subcutaneous tissue disorders1/52/6
Abdominal pain upperGastrointestinal disorders1/50/6
Aspartate aminotransferase increasedInvestigations1/50/6
Back painMusculoskeletal and connective tissue disorders1/50/6
BronchitisInfections and infestations1/51/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PlaceboTotal
Mean71.8 ± 13.0461.2 ± 16.7766.5 ± 15.37
Sex: Female, Male
Sex: Female, Male(Participants)Group A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PlaceboTotal
Female538
Male134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino6511
Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A : Ruxolitinib and Anagrelide PlaceboGroup B : Anagrelide and Ruxolitinib PlaceboTotal
White/Caucasian5611
Asian101
09

Study locations

26 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Compassionate Cancer Care Medical Group
    Riverside, California 92501, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Bond Clinic, PA
    Winter Haven, Florida 33880, United States
  • Tift Regional
    Tifton, Georgia 31794, United States
  • Edward Cancer Center
    Naperville, Illinois 60540, United States
  • North Shore Cancer Research Association-Skokie
    Skokie, Illinois 60076, United States
  • Southern Illinois University
    Springfield, Illinois 62702, United States
  • Clinical Trials of SWLA LLC
    Lake Charles, Louisiana 70601, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Summit Medical Group
    Morristown, New Jersey 07960, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC)
    New York, New York 10032, United States
  • Waverly Hem Onc
    Cary, North Carolina 27518, United States
  • Vidant Medical Center
    Greenville, North Carolina 27858, United States
  • Gabrail Cancer Center- Canton Facility
    Canton, Ohio 44718, United States
  • INTEGRIS Southwest Medical Center
    Oklahoma City, Oklahoma 73109, United States
  • INTEGRIS Cancer Institute Proton Campus
    Oklahoma City, Oklahoma 73142, United States
  • Kaiser Permanente Northwest
    Portland, Oregon 97227, United States
  • Geisinger - Knapper Clinic
    Danville, Pennsylvania 17822, United States
  • Prairie Lakes Health Care System Inc.
    Watertown, South Dakota 57201, United States
  • Renovatio Clinical
    The Woodlands, Texas 77401, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Aug 2020, 32 months.

Results were first posted in Nov 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2017
First posted
Apr 21, 2017
StartActual
Nov 14, 2017
Primary completionActual
Aug 3, 2020
CompletionActual
Aug 3, 2020
Results first posted
Nov 19, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03123588
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
Nov 14, 2017
Primary completion
Aug 3, 2020
Completion
Aug 3, 2020
Results posted
Nov 19, 2021
Last update
Nov 19, 2021

Study contacts

Albert Assad, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion